You are here

Emerging Infections

Beyond its mission to battle the global HIV epidemic, MHRP's extensive research infrastructure and capabilities allow the program's scientists to develop measures to counter emerging infectious disease threats and support outbreak response. 

In the past five years, MHRP has leveraged its expertise to initiate four Ebola vaccine studies in the U.S. and Africa and conduct a first-in-human trial of a Middle East Respiratory Syndrome vaccine. Most recently, burgeoning concerns over Zika virus complications have focused the program's efforts to build on WRAIR's existing foundation of flavivirus research to address this currently emerging threat.